Abstract
Dimerization of epidermal growth factor receptor (EGFR) on the cell membrane of tumor cells has been implicated in triggering a complex signal cascade that leads to increased tumor proliferation and survival. Cetuximab is a human-murine chimeric monoclonal antibody designed to target EGFR and competitively inhibit dimerization by circulating ligands. By this mechanism, it works to prevent this signal cascade thus hindering tumor proliferation. Cetuximab has been shown in a randomized phase III clinical trial to significantly increase overall survival when it is added to radiation therapy in the treatment of locally advanced squamous cell carcinoma of the head and neck. In this manuscript, the mechanism of cetuximab with its associated patents is reviewed, with its role with chemotherapy and radiation in the management of head and neck cancer along with future directions of this targeted cancer therapy.
Keywords: Cetuximab, squamous cell carcinoma of the head and neck, radiation therapy, concurrent chemotherapy and radiation, epidermal growth factor receptor, targeted therapy
Recent Patents on Anti-Cancer Drug Discovery
Title: Cetuximab: Its Use in Combination with Radiation Therapy and Chemotherapy in the Multimodality Treatment of Head and Neck Cancer
Volume: 3 Issue: 2
Author(s): Timothy D. Wagner and Gary Y. Yang
Affiliation:
Keywords: Cetuximab, squamous cell carcinoma of the head and neck, radiation therapy, concurrent chemotherapy and radiation, epidermal growth factor receptor, targeted therapy
Abstract: Dimerization of epidermal growth factor receptor (EGFR) on the cell membrane of tumor cells has been implicated in triggering a complex signal cascade that leads to increased tumor proliferation and survival. Cetuximab is a human-murine chimeric monoclonal antibody designed to target EGFR and competitively inhibit dimerization by circulating ligands. By this mechanism, it works to prevent this signal cascade thus hindering tumor proliferation. Cetuximab has been shown in a randomized phase III clinical trial to significantly increase overall survival when it is added to radiation therapy in the treatment of locally advanced squamous cell carcinoma of the head and neck. In this manuscript, the mechanism of cetuximab with its associated patents is reviewed, with its role with chemotherapy and radiation in the management of head and neck cancer along with future directions of this targeted cancer therapy.
Export Options
About this article
Cite this article as:
Wagner D. Timothy and Yang Y. Gary, Cetuximab: Its Use in Combination with Radiation Therapy and Chemotherapy in the Multimodality Treatment of Head and Neck Cancer, Recent Patents on Anti-Cancer Drug Discovery 2008; 3 (2) . https://dx.doi.org/10.2174/157489208784638776
DOI https://dx.doi.org/10.2174/157489208784638776 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Systemic Treatments for Adult Patients with Moderate-to-Severe Psoriasis:
Consensus Statements for the United Arab Emirates
New Emirates Medical Journal An Investigative Approach to Treatment Modalities for Squamous Cell Carcinoma of Skin
Current Drug Delivery The DNA-Binding and Bioactivity of Rare Earth Metal Complexes
Mini-Reviews in Medicinal Chemistry Endoglin-Targeted Cancer Therapy
Current Drug Delivery miRNA 21: Diagnostic Prognostic and Therapeutic Marker for Oral Cancer
MicroRNA Histone Modifications as Molecular Targets in Nasopharyngeal Cancer
Current Medicinal Chemistry Cyclooxygenase as a Target for Colorectal Cancer Chemoprevention
Current Drug Targets Applications of HPLC-MALDI-TOF MS/MS Phosphoproteomic Analysis in Oncological Clinical Diagnostics
Current Proteomics Roles of EGFR, PI3K, AKT, and mTOR in Heavy Metal-Induced Cancer
Current Cancer Drug Targets The Role of B-Lymphocyte Stimulator in Neuroendocrine Tumors: Correlation with Tumor Differentiation, Disease status and the Presence of Metastases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Matrix Metalloproteinases
Current Medicinal Chemistry Employing New Cellular Therapeutic Targets for Alzheimers Disease: A Change for the Better?
Current Neurovascular Research Design of New Improved Curcumin Derivatives to Multi-targets of Cancer and Inflammation
Current Drug Targets Subject Index To Volune 2
Current Cancer Therapy Reviews Radiolabeled RGD Peptides as Integrin alpha(v)beta3–targeted PET Tracers
Current Medicinal Chemistry Differentiation Between Osteoporotic and Neoplastic Vertebral Fractures: State of The Art and Future Perspectives
Current Medical Imaging Review on EGFR Inhibitors: Critical Updates
Mini-Reviews in Medicinal Chemistry Inhibitors of Apoptosis Proteins (IAPs) as Potential Molecular Targets for Therapy of Hematological Malignancies
Current Molecular Medicine Ectopic Thyroid Gland: Description of a Case and Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets Selected Players in the Inflammation Cascade and Drugs That Target These Inflammation Genes Against Metastasis
Anti-Cancer Agents in Medicinal Chemistry